Retatrutide cholesterol effects — looking for input

InsuranceTom said:

The phase 2 numbers were about 24% mean weight loss at 48 weeks on the top dose, with the curve still descending at the end of the study.

Careful with treating an unchanged LDL-C as a failure. If ApoB and triglycerides both fell, the particle picture improved regardless of what the calculated LDL says.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

One concrete data point for the thread. For anyone tracking the class: GLP-1 alone gets you appetite, GLP-1 plus GIP adds tolerability and lipid handling, and adding glucagon adds expenditure and liver-fat reduction. Each addition also adds a receptor system that can generate side effects.

Dr.LipidDallas said:

Careful with treating an unchanged LDL-C as a failure.

Before/after bloodwork compilation for the lipid panel — everything in one place for those who want comprehensive data:

Every single metabolic marker improved. This is why I'm a believer in this therapy.

A narrower follow-up, since the general answer is now clear:

Why adding glucagon agonism to an anti-obesity drug is not self-defeating, given that glucagon raises blood glucose?

Closing the loop on my own question.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.